News

US FDA: Development of New Tuberculosis Drug Regimens-Scientific and Clinical Design Considerations

The United States Food and Drug Administration held a public workshop regarding scientific and clinical trial design considerations for development of new tuberculosis drug regimens. This public workshop was intended to provide information for and gain perspective pertaining to development efforts around new in vitro and in vivo models, new biomarkers and tuberculosis diagnostics, assessing the contribution of 2 or more new components used in combination for to a tuberculosis regimen and clinical trial design challenges.

The TB Workshop transcript is available here and the details of the workshop are on the FDA's website

More News
27 Sep 2017
In a sign of increasing political will in the battle against the world’s top infectious killer, the heads of the World Health Organization and USAID voiced their support for the global fight against tuberculosis last week in a reception during the United Nations General Assembly. Advocates had been...
4 May 2017
Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today...
11 Apr 2017
Scientist at Rutgers University and their collaborators have published an article in Molecular Cell illustrating the three-dimensional structure of the drug target for the drug rifampicin. The abstract for the article is below. TITLE: Structural Basis of Mycobacterium tuberculosis Transcription and...